Recent Publications
Mount DL, Davis C, Kennedy B, Raatz S, Dotson K, Gary-Webb TL, Thomas S, Johnson KC, Espeland MA, Bahnson J, Wagenknecht L, Reboussin D, Rejeski WJ, Lang W, Bertoni A, Vitolins M, Miller G, Ribisl P, Hodges A,.
Factors influencing enrollment of African Americans in the Look AHEAD trial. Clin Trials. 2012;9(1):80-89.
Faulconbridge LF, Wadden TA, Rubin RR, Wing RR, Walkup MP, Fabricatore AN, Coday M, Van Dorsten B, Mount DL, Ewing LJ, Espeland MA, Bahnson JL, Wagenknecht L, Reboussin D, Rejeski WJ, Bertoni A, Lang W, Miller G, Lefkowitz D,.
One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity (Silver Spring). 2012;20(4):783-793.
Schwartz AV, Johnson KC, Kahn SE, Shepherd JA, Nevitt MC, Peters AL, Walkup MP, Hodges A, Williams CC, Bray GA, Espeland MA, Bahnson JL, Wagenknecht L, Reboussin D, Rejeski WJ, Bertoni A, Lang W, Miller G, Lefkowitz D, Reynolds PS,.
Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619-627.
Belalcazar LM, Ballantyne CM, Lang W, Rushing J, Espeland MA, Bahnson JL, Wagenknecht L, Reboussin D, Rejeski WJ, Bertoni A, Miller G, Lefkowitz D, Reynolds PS, Ribisl P, Vitolins M, Booth M, Dotson KM, Hodges A, Williams CC,.
Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the Look AHEAD study. Arterioscler Thromb Vasc Biol. 2011;31(7):1689-1695.
Mychaleckyj JC, Noble JA, Moonsamy PV, Carlson JA, Varney MD, Post J, Pierce JJ, Williams DT, Perdue LH, Reboussin DM, et al.
HLA genotyping in the international Type 1 Diabetes Genetics Consortium. Clin Trials. 2010;7(Suppl 1):S75-S87.
Wing RR, Bahnson JL, Bray GA, Clark JM, Coday M, Egan C, Espeland MA, Reboussin D, Rejeski WJ, Wagenknecht L, et al.
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.
Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, Wadden TA, Kelley D, Wing RR, Reboussin D, et al.
A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619-1626.
Adams PC, Barton JC, McLaren GD, Acton RT, Speechley M, McLaren CE, Reboussin DM, Leiendecker-Foster C, Harris EL, Snively BM, et al.
Screening for iron overload: lessons from the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Can J Gastroenterol. 2009;23(11):769-772.
Belalcazar M, Reboussin D, Haffner S, Hoogeveen R, Tracy R, Kriska A, Schwenke D, Pi-Sunyer X, Ballantyne C. Improvement in glucose control with lifestyle intervention reduces C-reactive protein in obese subjects with type 2 diabetes: the Look AHEAD Study [abstract]. Circulation. 2009;120(18 Suppl 2):S473-S474.
McLaren CE, Garner CP, Constantine CC, Masle S, Vulpe CD, Snively BM, Cook JD, Nickerson DA, Leiendecker-Foster C, Reboussin DM, et al. Genome-wide association study identifies genetic loci associated with iron deficiency [abstract]. Blood. 2009;114(22):1552-1553.
Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, Eckfeldt JH, McLaren CE, Reiss JA, McLaren GD, Reboussin DM, et al.
Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. Am J Hematol. 2008;83(2):126-132.
McLaren CE, Gordeuk VR, Chen W-P, Barton JC, Acton RT, Speechley M, Castro O, Adams PC, Snively BM, Reboussin DM, et al.
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Transl Res. 2008;151(2):97-109.
Adams PC, Reboussin DM, Barton JC, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren CE, McLaren GD, et al.
Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Int J Lab Hematol. 2008;30(4):300-305.
Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, Acton RT, McLaren GD, Harris EL, Reiss JA, Adams PC, Passmore L, et al.
Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol. 2008;83(8):618-626.
McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Snively BM, et al.
Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol. 2008;22(11):923-930.
Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Snively BM, Passmore LV, et al.
Serum ferritin and transferrin saturation in Asians and pacific islanders. Arch Intern Med. 2007;167(7):722-726.
Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, Leiendecker-Foster C, Press RD, Adams PC, Reboussin DM, et al.
Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. 2007;38(3):247-252.
Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins RW, Lovato L, et al. Non-fasting serum transferrin saturation (TS) is similar to fasting TS for the detection of C282Y homozygotes for hemochromatosis [abstract]. Am J Hematol. 2007;82(6):575.
Adams PC, Reboussin DM, Barton JC, McLaren CE, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren GD, et al. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study [abstract]. Am J Hematol. 2007;82(6):595-596.
McLaren CE, Harris EL, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Snively BM, Passmore LV, et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders living in the U.S. and Canada: the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Am J Hematol. 2007;82(6):574.
McLaren GD, Gordeuk VR, Reboussin DM, Barton JC, Acton RT, McLaren CE, Harris EL, Reiss JA, Adams PC, Passmore L, et al. Serum ferritin concentration and body iron stores among 101,168 primary care participants [abstract]. Am J Hematol. 2007;82(6):594-595.
McLaren CE, Barton JC, Gordeuk VR, Wu L, Adams PC, Reboussin DM, Speechley M, Chang H, Acton RT, Ruggiero AM, et al.
Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Am J Hematol. 2007;82(10):898-905.
Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Lovato L, et al.
Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007;120(11):999.e1-7.
Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, et al.
HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. Genet Test. 2007;11(3):269-275.
McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley M, Snively BM, et al. Symptoms, signs, and clinical conditions in HFE C282Y homozygotes identified by screening in primary care [abstract]. Am J Hematol. 2007;82(6):553.
Adams PC, Reboussin DM, Barton JC, Gordeuk VR, Leiendecker-Foster C, McLaren CE, Acton RT, Eckfeldt JH, Dawkins FW, Snively BM, et al. Iron removed by quantitative phlebotomy in participants identified from a multi-ethnic, primary care sample [abstract]. Am J Hematol. 2007;82(6):558.
Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton JC, McIaren GD, Eckfeldt JH, Dawkins FW, Gordeuk VR, et al.
Liver diseases in the Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol. 2006;4(7):918-923.
Espeland MA, Bahnson J, Wagenknecht, Reboussin D, Rejeski WJ, Lang W, Bertoni A, Vitolins M, Miller G, Ribisl P, Dotson K, Hodges A, Hogan P, et al.
The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14(5):737-752.
McLaren CE, Li K-T, McLaren GD, Gordeuk VR, Snively BM, Reboussin DM, Barton JC, Acton RT, Dawkins FW, Harris EL, et al.
Mixture models of serum iron measures in population screening for hemochromatosis and iron overload. Transl Res. 2006;148(4):196-206.
Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, et al.
Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care. 2006;29(9):2084-2089.
Lamon-Fava S, Mayer J, Herrington DM, Reboussin DM, Schaefer EJ, Asztalos BF, Mayer J. High density lipoprotein subpopulations and lipoprotein remnants: effects of hormonal replacement therapy and association with baseline coronary atherosclerosis in the Estrogen Replacement and Atherosclerosis (ERA) trial [abstract]. Circulation. 2006;114(18 Suppl):255.
Adams PC, Reboussin DM, McLaren CE, Barton JC, Acton RT, Lovato L, McLaren GD, Moses GC, Press R, Chang H, et al. Do the biological variability of transferrin saturation and unsaturated iron binding capacity limit their utility as screening tests for HFE C282Y-linked hemochromatosis? [abstract]. Hepatology. 2006;44(4 Suppl):432A-433A.
McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley M, Snively BM, et al. Symptoms and signs of hemochromatosis in HFE C282Y homozygotes identified by screening in primary care [abstract]. Blood. 2006;108(11 Pt 1):444a.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.